268 related articles for article (PubMed ID: 33632218)
21. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
Fitzpatrick C; Floyd K
Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.
Kasaie P; Pennington J; Gupta A; Dowdy DW; Kendall EA
Clin Infect Dis; 2024 Jan; 78(1):133-143. PubMed ID: 37724763
[TBL] [Abstract][Full Text] [Related]
23. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
Portnoy A; Clark RA; Quaife M; Weerasuriya CK; Mukandavire C; Bakker R; Deol AK; Malhotra S; Gebreselassie N; Zignol M; Sim SY; Hutubessy RCW; Baena IG; Nishikiori N; Jit M; White RG; Menzies NA
PLoS Med; 2023 Jan; 20(1):e1004155. PubMed ID: 36693081
[TBL] [Abstract][Full Text] [Related]
24. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
[TBL] [Abstract][Full Text] [Related]
25. [Progress in research of prophylactic therapy in contacts of rifampicin-resistant tuberculosis patients].
Wang Z; Wang WJ; Ding XY; Lu P; Zhu LM; Liu Q; Lu W
Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Mar; 44(3):470-476. PubMed ID: 36942344
[TBL] [Abstract][Full Text] [Related]
26. Genotype analysis of ofloxacin-resistant multidrug-resistant
Gupta A; Sinha P; Rathod S; Shanmugam SK; Uma Devi KR; Anupurba S; Nema V
Indian J Med Res; 2020 Apr; 151(4):361-370. PubMed ID: 32461400
[TBL] [Abstract][Full Text] [Related]
27. Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India.
Ahmed S; Shukla I; Fatima N; Varshney SK; Shameem M; Tayyaba U
Int J Mycobacteriol; 2018; 7(4):315-327. PubMed ID: 30531028
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
29. Potential impact of tuberculosis vaccines in China, South Africa, and India.
Harris RC; Sumner T; Knight GM; Zhang H; White RG
Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 33028708
[TBL] [Abstract][Full Text] [Related]
30. The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin.
Liang Y; Wu X; Zhang J; Li N; Yu Q; Yang Y; Bai X; Liu C; Shi Y; Liu Q; Zhang P; Li Z
Vaccine; 2008 Aug; 26(35):4536-40. PubMed ID: 18602439
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of routine adolescent vaccination with an M72/AS01
Harris RC; Quaife M; Weerasuriya C; Gomez GB; Sumner T; Bozzani F; White RG
Nat Commun; 2022 Feb; 13(1):602. PubMed ID: 35105879
[TBL] [Abstract][Full Text] [Related]
32. Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs.
Liang Y; Wu X; Zhang J; Yang Y; Wang L; Bai X; Yu Q; Li N; Li Z
Scand J Immunol; 2011 Jul; 74(1):42-6. PubMed ID: 21352251
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.
Tseng CL; Oxlade O; Menzies D; Aspler A; Schwartzman K
BMC Public Health; 2011 Jan; 11():55. PubMed ID: 21269503
[TBL] [Abstract][Full Text] [Related]
34. Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness.
Arinaminpathy N; Nandi A; Vijayan S; Jha N; Nair SA; Kumta S; Dewan P; Rade K; Vadera B; Rao R; Sachdeva KS
BMJ Glob Health; 2021 Oct; 6(10):. PubMed ID: 34610905
[TBL] [Abstract][Full Text] [Related]
35. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis.
Menzies NA; Allwood BW; Dean AS; Dodd PJ; Houben RMGJ; James LP; Knight GM; Meghji J; Nguyen LN; Rachow A; Schumacher SG; Mirzayev F; Cohen T
Nat Commun; 2023 Oct; 14(1):6182. PubMed ID: 37794037
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of decentralised care model for managing MDR-TB in India.
John D; Chatterjee P; Murthy S; Bhat R; Musa BM
Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
[TBL] [Abstract][Full Text] [Related]
37. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Laurence YV; Griffiths UK; Vassall A
Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
Fan Q; Ming WK; Yip WY; You JHS
Int J Infect Dis; 2019 Jan; 78():44-49. PubMed ID: 30342251
[TBL] [Abstract][Full Text] [Related]
39. Drug resistance and associated genetic mutations among patients with suspected MDR-TB in Uttar Pradesh, India.
Jain A; Singh PK; Chooramani G; Dixit P; Malhotra HS
Int J Tuberc Lung Dis; 2016 Jul; 20(7):870-5. PubMed ID: 27287637
[TBL] [Abstract][Full Text] [Related]
40. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
